AANextra AN OFFICIAL PUBLICATION OF THE AMERICAN ACADEMY OF NEUROLOGY
Tuesday, April 5, 2022
IMPORTANT CLINICAL TRIALS SHOWCASED IN TODAY'S PLENARY The Clinical Trials Plenary Session is set to take place this morning from 9:15 a.m. to 11:30 a.m. in Hall 4A. The session will showcase experts presenting the latest updates within several clinical trials that affect patient care, conducted over the course of the last year and identified from other society meetings.
A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia
Robert A. Hauser, MD, MBA, FAAN University of South Florida
Moderators
Relapse Rate and Time to First Relapse Were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS) Lawrence Steinman, MD, FAAN Stanford Medicine
AAN Science Committee Members
H E Hinson, MD, MCR, FAAN Oregon Health & Science University
Reena Parada Thomas, MD Stanford Cancer Center
Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Antiacetylcholine Reception Antibodypositive Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Study Tuan Hoang Vu, MD University of South Florida
What is your aha moment from the Clinical Trials Plenary Session? Join the conversation at #AANAM.
INSIDE
4
Today Is National Institutes of Health DayâTake Part in These Special Events!
5
IDEAS Panel to Discuss New Online Anti-racism Education Program
6
Latest Innovations of Significance Highlighted in Emerging Science Abstracts
Efficacy and Safety Outcomes in Patients with Chronic Traumatic Brain Injury: Final Analysis of the Phase 2 Stemtra Trial Peter J. McAllister, MD, FAAN New England Institute for Neurology and Headache
Live Fireside Chat to Follow Clinical Trials Plenary Session Head over to the Research Connections Learner Engagement Center in Hall 4C-4 from 11:45 a.m. to 12:15 p.m. to engage with and ask questions of plenary moderators and presenters during the live, 30-minute fireside chat!
MR CLEAN-NO IV: Intravenous Treatment Followed by Endovascular Treatment Versus Direct Endovascular Treatment for Acute Ischemic Stroke Caused by a Proximal Intracranial Occlusion-study Protocol for a Randomized Clinical Trial Natalie LeCouffe, MD Amsterdam UMC
Clinical Efficacy of ONC201 in Recurrent H3 K27M-Mutant Diffuse Midline Glioma Patients Isabel ArrillagaRomany, MD Massachusetts General Hospital
Efficacy and Safety of Trofinetide for the Treatment of Rett Syndrome: Results From the Pivotal Phase 3 LAVENDER Study Jeffrey Neul, MD, PhD Vanderbilt University Medical Center